Tommaso Farolfi
Overview
Explore the profile of Tommaso Farolfi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caputo D, Cammarata R, Farolfi T, Coppola R, La Vaccara V
ANZ J Surg
. 2024 Mar;
94(7-8):1299-1304.
PMID: 38553884
Backgrounds: Rectal robotic surgery gained momentum in the last decade, but it is still associated with not-negligible costs. In order to reduce costs, recently different robotic systems have received approval...
2.
Caputo D, Farolfi T, Molina C, Coppola R
ANZ J Surg
. 2023 Nov;
94(3):387-390.
PMID: 37984555
Background: The Hugo RAS™ system (Medtronic, Minneapolis, MN, USA), approved for gynaecological and urological procedures, has been recently certified for the use in few general surgeries. Only bariatric and colorectal...
3.
La Vaccara V, Coppola A, Cammarata R, Olivieri L, Farolfi T, Coppola R, et al.
J Gastrointest Oncol
. 2023 Nov;
14(5):2158-2166.
PMID: 37969843
Background: Pancreatoduodenectomy (PD) is a complex surgical procedure known for its significant morbidity rates, and the presence of an aberrant hepatic artery (AHA) introduces additional challenges. The impact of AHA...
4.
Coppola A, La Vaccara V, Farolfi T, Asbun H, Boggi U, Conlon K, et al.
Int J Surg
. 2023 Sep;
110(10):6092-6099.
PMID: 37738016
Introduction: Lymph-nodal involvement (N+) represents an adverse prognostic factor after pancreatoduodenectomy (PD) for pancreatic adenocarcinoma (PDAC). Preoperative diagnostic and staging modalities lack sensitivity for identifying N+. This study aimed to...
5.
Gallo P, Silletta M, Prinzi F, Farolfi T, Coppola A
J Clin Med
. 2023 Jul;
12(14).
PMID: 37510720
Hepatocellular Carcinoma (HCC) is a leading cause of cancer-related deaths worldwide [...].
6.
Coppola A, Farolfi T, La Vaccara V, Iannone I, Giovinazzo F, Panettieri E, et al.
J Clin Med
. 2023 Jun;
12(11).
PMID: 37297872
Background: Pancreatic ductal adenocarcinoma (PDAC) represents a challenging disease for the surgeon, oncologist, and radiation oncologist in both diagnostic and therapeutic settings. Surgery is currently the gold standard treatment, but...
7.
Coppola A, La Vaccara V, Angeletti S, Spoto S, Farolfi T, Cammarata R, et al.
J Gastrointest Oncol
. 2023 May;
14(2):1077-1086.
PMID: 37201045
Background: Early detection and therapy of pancreatic fistula after pancreaticoduodenectomy is crucial to improve outcomes of this surgery. Since it is not clear if procalcitonin (PCT), can predict the onset...
8.
La Vaccara V, Cascone C, Coppola A, Farolfi T, Cammarata R, Emerenziani S, et al.
Ann Ital Chir
. 2023 Feb;
94:45-51.
PMID: 36810297
Aim: The aim of this monocentric retrospective study was to investigate the relation between sarcopenia, postoperative complications and survival in patients undergoing radical surgery for pancreatic ductal adenocarcinoma (PDAC). Material...
9.
Coppola A, Farolfi T, La Vaccara V, Cammarata R, Caputo D
J Clin Med
. 2022 Nov;
11(21).
PMID: 36362735
Pancreatic ductal adenocarcinoma (PDAC) is considered one of the "Big Five" lethal cancers, which include lung, bowel, breast and prostate cancer [...].
10.
Coppola A, Cammarata R, La Vaccara V, Farolfi T, Caputo D
J Clin Med
. 2022 Nov;
11(21).
PMID: 36362650
Although the mortality at 90 days has declined, pancreaticoduodenectomy (PD) is an extremely complex surgical procedure, with a non-negligible rate of major postoperative complications [...].